• Early Stage Start-Up Director

Jessica Sletten joined Segal trials in 2018 in the role of Early Stage Start-Up Director. Her role is focused on growing and furthering the operations of the early stage business units of Segal Trials. Jessica obtained her bachelor’s degree in Psychology from the University of Montana and is a current Master of Business Administration candidate at Rollins College, graduating in May 2019. Jessica has been in the broader field of healthcare for 25 years, starting her career managing hospitals and partial hospitalization programs focused on the treatment of traumatic brain injuries and mental health disorders. She has spent the last 15 years in clinical research, working in a broad range of capacities starting with coordinating and rating visits, managing quality assurance and recruitment functions, providing oversight for research units and sites and, most recently, directing clinical operations for a large network of study sites. Jessica has experience in all phases of clinical research across multiple indications including Psychiatry, General Medicine, Pain and Neurology. She has worked on over 1,000 outpatient clinical trials and was directly responsible for the management of 5 successful FDA inspections all ending with no major findings. She has also had responsibility for over 100 inpatient or Phase 1 trials, both in healthy normal subjects and in special populations, including PK trials, first-in-human dosing trials, and studies requiring continuous CSF sampling. Jessica is passionate about clinical research and has a special interest in operations and network development. She specializes in building and training teams, creating and ensuring efficient systems to support safe and quality data collection, and the growth and development of site capabilities. Jessica’s focus is on growing and developing the individuals committed to clinical research and on honing the efficiency of the systems they depend on. Through this, she hopes to have a continued positive effect on the industry overall and on the safety and availability of interventions for patients with in the healthcare system.